Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polycythemia rubra vera

S Bilgrami1, B R Greenberg

  • 1Division of Hematology/Oncology, University of Connecticut Health Center, Farmington 06030, USA.

Seminars in Oncology
|August 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world lipid lowering effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: A single-centre study.

International journal of cardiology·2020
Same author

Acquired hemophilia in chronic lymphocytic leukemia.

Leukemia & lymphoma·2007
Same author

Abdominal presentation of Burkitt's lymphoma in an HIV-positive patient.

AIDS patient care and STDs·2004
Same author

Unusual extramedullary relapse of CML.

Annals of oncology : official journal of the European Society for Medical Oncology·2004
Same author

Multiple myeloma and hairy cell leukemia: a rare association or coincidence?

Leukemia & lymphoma·2001
Same author

Efficacy of clarithromycin in preventing viridans streptococcal bacteremia following autologous stem cell transplantation.

Infection·2001
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Polycythemia vera (PV) is a clonal disorder of excessive erythropoiesis. Treatment focuses on preventing complications like thrombosis and leukemia, with phlebotomy and specific therapies improving survival.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Polycythemia vera (PV) is a clonal disorder marked by excessive red blood cell production and low erythropoietin (EPO) levels.
  • Pathophysiology involves EPO-sensitive malignant erythroid progenitors, leading to complications like thrombosis and potential progression to myelofibrosis or leukemia.

Purpose of the Study:

  • To outline the pathophysiology, diagnostic criteria, and therapeutic strategies for polycythemia vera.
  • To emphasize the importance of preventing thrombohemorrhagic complications and managing disease progression.

Main Methods:

  • Review of established diagnostic criteria for PV.
  • Analysis of treatment outcomes from studies like the PVSG trials.
  • Evaluation of various therapeutic agents including phlebotomy, 32P, chlorambucil, hydroxyurea, and interferon (IFN).

Related Experiment Videos

Main Results:

  • Phlebotomy to a hematocrit ≤45% is the initial treatment.
  • 32P and phlebotomy demonstrate equivalent superior survival rates compared to chlorambucil, which increases malignancy risk.
  • Elderly patients (>70 years) benefit from initial phlebotomy and myelosuppressive therapy (e.g., 32P) due to thrombotic risks.

Conclusions:

  • Accurate diagnosis allows for a >10-year survival, with management focused on preventing complications.
  • Therapeutic choices involve balancing efficacy with risks of secondary malignancies and thrombosis.
  • Hydroxyurea and IFN show promise, with IFN potentially becoming a future standard therapy.